CN101341167B - 大环内酯类抗生素的纯化方法 - Google Patents
大环内酯类抗生素的纯化方法 Download PDFInfo
- Publication number
- CN101341167B CN101341167B CN200680045911XA CN200680045911A CN101341167B CN 101341167 B CN101341167 B CN 101341167B CN 200680045911X A CN200680045911X A CN 200680045911XA CN 200680045911 A CN200680045911 A CN 200680045911A CN 101341167 B CN101341167 B CN 101341167B
- Authority
- CN
- China
- Prior art keywords
- macrolide antibiotics
- purification
- less
- purifying
- ultrafiltration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
本发明涉及一种大环内酯类抗生素的纯化方法。更具体地,其涉及一种用以得到白色粉末大环内酯类抗生素的纯化方法。该粉末在储存一段时间之后仍保持白色。本发明的方法是这样进行的:将大环内酯类抗生素例如商品盐酸万古霉素溶于水,所得溶液用标称截留分子量小于30,000道尔顿,最好是10,000道尔顿的膜进行超滤。纯化后溶液最好用反渗透法进行浓缩,然后在优化的压力和温度条件下冻干,以得到白色粉末。
Description
本发明涉及一种大环内酯类抗生素的纯化方法。更具体地,其涉及一种用以得到白色粉末的大环内酯类抗生素的纯化方法。该粉末在储存一段时间之后仍保持白色。
大环内酯类抗生素具有大环内酯化学结构,是一种可连接有糖的具有12~22个碳原子的内酯环。它们可抑制细菌繁殖,并与细菌的核糖体结合,阻止蛋白质的生成。
大环内酯类抗生素包括万古霉素、替考拉宁(teicoplanin)、红霉素、阿奇霉素、克拉霉素、罗红霉素、交沙霉素、利托霉素、艾替诺丁(actinoidin)、阿伏霉素、阿克他宁(actaplanin)、替考霉素(teichomycin)和泰利霉素。
一般地,本发明涉及大环内酯类抗生素的纯化,更具体地涉及万古霉素的纯化。
US 5,853,720公开了一种纯化万古霉素的方法,其纯化步骤采用硅胶柱制备色谱法。
EP 132 117公开了采用亲和色谱的万古霉素类抗生素的纯化方法,其中,通过形成吸附复合物,抗生素与基体结合。
这些基于色谱技术的方法,可生产出纯度提高的抗生素,但不能生产出令人满意的白色粉末。对于万古霉素,在色谱纯化后,初始颜色是淡粉红色,过一段时间后,其颜色变成褐色。这不符合欧洲药典要求。
现已发现,通过对大环内酯类抗生素进行超滤,可以除去在450nm下具有高吸光度的杂质。
超滤是分离不同大小分子的方法。在超滤中,虽然如分子的形状、电荷等其它次要因素也起到作用,但实际上是分子的分子量起最重要的作用。在市场上,可获得按照被膜截留分子的分子量来定义的不同超滤膜。适用于本发明的膜的截留分子量为低于30,000道尔顿。
本发明的方法是这样进行的:将大环内酯类抗生素例如商品盐酸万古霉素溶于水,所得溶液用标称截留分子量小于30,000道尔顿的膜进行超滤,所用膜的截留分子量,以等于或小于15,000道尔顿为佳,等于或小于10,000道尔顿最佳。优选地,超滤膜的标称截留分子量大于6,000道尔顿。纯化后溶液最好用反渗透进行浓缩,然后在优化的压力和温度条件下冻干,以得到白色粉末。如果需要得到无菌粉末,最好将该溶液,在进行反渗透浓缩后,通过0.22微米的过滤器,并将滤液收集于无菌容器(根据欧洲GMP标准的A级)。
膜的类型取决于抗生素。对于万古霉素,采用截留分子量30,000道尔顿的膜,万古霉素可以通过该膜,而杂质保留在滞留液中。相反,使用10,000道尔顿的膜,可以有效地纯化替考拉宁。这样,杂质在透过液中,而替考拉宁在滞留液中。因此,对各种抗生素,都可对膜的类型作最优化选择,以实现杂质和大环内酯类抗生素的最佳分离。
当抗生素为万古霉素时,其在450nm处检定的吸收值为0.100,最好小于0.080。
将大环内酯类抗生素溶于水,在初始溶液中该抗生素的浓度为0.1~30重量%,优选为1~20重量%,最好为3~18重量%。
实施例
实施例所用盐酸万古霉素是从Alpharma公司获得的商品。
在450nm下的吸光度是根据欧洲药典中万古霉素专论的规定测得的。
实施例1盐酸万古霉素的纯化
将65g Alpharma公司产的商品盐酸万古霉素溶于500ml蒸馏水。待粉末完全溶解后,所得溶液用10,000道尔顿的膜进行超滤,在透过液和滞留液之间维持1bar的压降,而跨膜压降为2.5bar。透过液经反渗透浓缩,再通过0.22微米过滤器,然后收集于符合欧洲GMP标准的A级容器内。
实施例2盐酸万古霉素的纯化
将30g Alpharma公司产的商品盐酸万古霉素溶于500ml蒸馏水。待粉末完全溶解后,用10,000道尔顿的膜对该溶液进行超滤,在透过液和滞留液之间维持1bar的压降,而跨膜压降为2.5bar。透过液经反渗透浓缩,再通过0.22微米过滤器,然后收集于符合欧洲GMP标准的A级容器。
初始万古霉素实 施例1 实施例2
450nm吸光度 0.184 0.064 0.045
实施例3替考拉宁的纯化
将10g替考拉宁溶于100ml蒸馏水。待粉末完全溶解后,所得溶液用10,000道尔顿的膜进行超滤,在透过液和滞留液之间维持1bar的压降,而跨膜压降为2.5bar。在此情况下,替考拉宁保留在滞留液中,而一些杂质通过到透过液中。滞留液通过0.22微米过滤器,收集于符合欧洲GMP标准的A级容器,然后在优化的温度和真空条件下冻干。
用高效液相色谱测得的替考拉宁的纯度在纯化前为89.7%,纯化后为93.8%。最重要的杂质在纯化前后分别为10.8%和6.1%,而纯化前为2.9%的第二杂质在纯化后全部消失。
Claims (5)
1.一种纯化万古霉素的方法,包括:将该万古霉素溶于水,然后该溶液用标称截留分子量小于30,000道尔顿的膜进行超滤。
2.如权利要求1所述的方法,其特征在于,所述膜的标称截留分子量等于或小于10,000道尔顿。
3.如权利要求1或2所述的方法,其特征在于,在超滤后,纯化后的溶液任选地由反渗透法进行浓缩,然后在优化的压力和温度条件下冻干得到白色粉末。
4.如权利要求1或2所述的方法,其特征在于,最终粉末在450nm的吸光度小于0.100。
5.如权利要求1或2所述的方法,其特征在于,所述最终粉末在450nm的吸光度小于0.080。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05112283.6 | 2005-12-16 | ||
EP05112283A EP1798237A1 (en) | 2005-12-16 | 2005-12-16 | Process for the purification of macrolide antibiotics |
PCT/EP2006/069414 WO2007068644A1 (en) | 2005-12-16 | 2006-12-07 | Process for the purification of macrolide antibiotics |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101341167A CN101341167A (zh) | 2009-01-07 |
CN101341167B true CN101341167B (zh) | 2012-08-15 |
Family
ID=36177625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200680045911XA Expired - Fee Related CN101341167B (zh) | 2005-12-16 | 2006-12-07 | 大环内酯类抗生素的纯化方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8268963B2 (zh) |
EP (2) | EP1798237A1 (zh) |
JP (1) | JP5124475B2 (zh) |
CN (1) | CN101341167B (zh) |
AT (1) | ATE457994T1 (zh) |
AU (1) | AU2006326070B2 (zh) |
CA (1) | CA2628798C (zh) |
DE (1) | DE602006012360D1 (zh) |
DK (1) | DK1960418T3 (zh) |
ES (1) | ES2340804T3 (zh) |
NO (1) | NO20082935L (zh) |
PL (1) | PL1960418T3 (zh) |
PT (1) | PT1960418E (zh) |
RU (1) | RU2400489C2 (zh) |
WO (1) | WO2007068644A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101101663B1 (ko) | 2009-01-13 | 2011-12-30 | (주) 제노텍 | 반코마이신 습체의 정제방법 |
ITLO20110001A1 (it) | 2011-05-03 | 2012-11-04 | Fisiopharma Srl | Flaconi di vancomicina cloroidrata con stabilità migliorata |
EP2592090A1 (en) * | 2011-11-11 | 2013-05-15 | LEK Pharmaceuticals d.d. | Process of purification of teicoplanin |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1224021A (zh) * | 1998-01-22 | 1999-07-28 | 清华大学 | 用环烷酸萃取体系提取和纯化抗生素 |
CN1554773A (zh) * | 2003-12-26 | 2004-12-15 | 三达膜科技(厦门)有限公司 | 应用膜提取发酵类大环内酯型抗生素的方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2288473A1 (fr) | 1974-10-22 | 1976-05-21 | Manche Union Coop Agr Laiti | Procede de traitement du lactoserum de fromagerie, notamment en vue de l'extraction de glycoproteides et d'acide sialique |
US4667024A (en) * | 1983-07-13 | 1987-05-19 | Smithkline Beckman Corporation | Process for the preparation of purified vancomycin class antibiotics |
JPH0689038B2 (ja) * | 1983-12-12 | 1994-11-09 | イーライ・リリー・アンド・カンパニー | バンコマイシン改良精製法およびその生産物 |
JPH0260598A (ja) * | 1988-08-22 | 1990-03-01 | Glaxo Group Ltd | 抗生物質の製造 |
JP2577133B2 (ja) | 1989-11-27 | 1997-01-29 | スティフティング フォール ド テフニスヘ ウェッテンスハッペン | 船舶のプロペラ |
US5258495A (en) * | 1990-07-10 | 1993-11-02 | Abbott Laboratories | Process for making vancomycin HC1 |
SI9500039B (sl) | 1995-02-07 | 2002-02-28 | Lek, | Nov kombiniran postopek čiščenja Vankomicin hidroklorida |
SI9500040B (sl) * | 1995-02-07 | 2002-02-28 | Lek, | Kromatografsko čiščenje Vankomicin hidroklorida z uporabo preparativne HPLC |
JPH10225299A (ja) * | 1996-12-11 | 1998-08-25 | Nippon Kayaku Co Ltd | バンコマイシンの製造方法 |
US6391851B1 (en) * | 1997-03-10 | 2002-05-21 | Fujisawa Pharmaceutical Co., Ltd. | Hydrochlorides of vancomycin antibiotics and process for producing the same |
JP4142149B2 (ja) | 1997-07-10 | 2008-08-27 | 明治製菓株式会社 | バンコマイシンの凍結乾燥製剤 |
KR100870660B1 (ko) * | 2001-12-31 | 2008-11-26 | 엘지디스플레이 주식회사 | 패널의 합착력이 향상된 액정표시소자 및 제조방법 |
KR100476818B1 (ko) * | 2002-07-19 | 2005-03-17 | 종근당바이오 주식회사 | 테이코플라닌 에이 투 정제 방법 |
KR100474653B1 (ko) * | 2004-04-16 | 2005-03-14 | 동국제약 주식회사 | 타이코플라닌의 고순도 생산방법 |
SI21924A (sl) | 2004-12-07 | 2006-06-30 | Lek Farmacevtska Druzba D.D. | Cist vankomicin hidroklorid |
-
2005
- 2005-12-16 EP EP05112283A patent/EP1798237A1/en not_active Withdrawn
-
2006
- 2006-12-07 PL PL06841295T patent/PL1960418T3/pl unknown
- 2006-12-07 US US12/095,642 patent/US8268963B2/en active Active
- 2006-12-07 DK DK06841295.6T patent/DK1960418T3/da active
- 2006-12-07 EP EP06841295A patent/EP1960418B1/en active Active
- 2006-12-07 ES ES06841295T patent/ES2340804T3/es active Active
- 2006-12-07 CA CA2628798A patent/CA2628798C/en not_active Expired - Fee Related
- 2006-12-07 CN CN200680045911XA patent/CN101341167B/zh not_active Expired - Fee Related
- 2006-12-07 AU AU2006326070A patent/AU2006326070B2/en not_active Ceased
- 2006-12-07 WO PCT/EP2006/069414 patent/WO2007068644A1/en active Application Filing
- 2006-12-07 PT PT06841295T patent/PT1960418E/pt unknown
- 2006-12-07 JP JP2008544968A patent/JP5124475B2/ja active Active
- 2006-12-07 AT AT06841295T patent/ATE457994T1/de active
- 2006-12-07 DE DE602006012360T patent/DE602006012360D1/de active Active
- 2006-12-07 RU RU2008128465/04A patent/RU2400489C2/ru not_active IP Right Cessation
-
2008
- 2008-06-30 NO NO20082935A patent/NO20082935L/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1224021A (zh) * | 1998-01-22 | 1999-07-28 | 清华大学 | 用环烷酸萃取体系提取和纯化抗生素 |
CN1554773A (zh) * | 2003-12-26 | 2004-12-15 | 三达膜科技(厦门)有限公司 | 应用膜提取发酵类大环内酯型抗生素的方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1960418B1 (en) | 2010-02-17 |
NO20082935L (no) | 2008-06-30 |
CN101341167A (zh) | 2009-01-07 |
AU2006326070B2 (en) | 2011-08-25 |
JP5124475B2 (ja) | 2013-01-23 |
DK1960418T3 (da) | 2010-05-31 |
RU2400489C2 (ru) | 2010-09-27 |
US8268963B2 (en) | 2012-09-18 |
JP2009519294A (ja) | 2009-05-14 |
PL1960418T3 (pl) | 2010-07-30 |
RU2008128465A (ru) | 2010-01-27 |
CA2628798C (en) | 2014-08-05 |
EP1960418A1 (en) | 2008-08-27 |
AU2006326070A1 (en) | 2007-06-21 |
EP1798237A1 (en) | 2007-06-20 |
ES2340804T3 (es) | 2010-06-09 |
PT1960418E (pt) | 2010-05-05 |
US20100228005A1 (en) | 2010-09-09 |
ATE457994T1 (de) | 2010-03-15 |
DE602006012360D1 (de) | 2010-04-01 |
CA2628798A1 (en) | 2007-06-21 |
WO2007068644A1 (en) | 2007-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1330049C (en) | Process for removing pyrogens | |
US6891037B1 (en) | Method for the isolation of polysaccharides | |
KR20160123284A (ko) | 고순도 반코마이신 염산염의 분리 정제방법 | |
CN101341167B (zh) | 大环内酯类抗生素的纯化方法 | |
JP2008506360A (ja) | テイコプラニンの高純度生産方法 | |
JP2659388B2 (ja) | 糖ペプチド回収方法 | |
CA1334655C (en) | De-mannosyl teicoplanin derivatives | |
EP2776452B1 (en) | Process of purification of teicoplanin | |
EP1824874B1 (en) | A processs for the purification of crude vancomycin | |
US5853720A (en) | Combined process for the purification of vancomycin hydrochloride | |
CN113004373A (zh) | 一种达托霉素的纯化方法 | |
CN101348494A (zh) | 高纯度盐酸头孢甲肟及其制备方法 | |
CN113563426B (zh) | 奥利万星母核a82846b的分离纯化方法 | |
CN102272320B (zh) | 纯化万古霉素湿体的方法 | |
MX2008007566A (en) | Process for the purification of macrolide antibiotics | |
KR100434109B1 (ko) | 테이코플라닌의 정제방법 | |
CN115260294A (zh) | 一种替考拉宁的分离纯化方法 | |
Kuriyel et al. | 14 Advancements in Membrane Processes for Pharmaceutical Applications | |
CN117362397A (zh) | 一种奥利万星的纯化方法 | |
JPH084503B2 (ja) | ウロキナーゼの回収方法及びそれにより得られるウロキナーゼ含有画分 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120815 Termination date: 20151207 |
|
EXPY | Termination of patent right or utility model |